Adaptive Phage Therapeutics (APT)

by Company Biotechnology Adaptive phage therapeutics APT

Adaptive Phage Therapeutics (APT) is a clinical-stage biotechnology company advancing therapies to treat multi-drug resistant infections. Prior approaches in antimicrobials have been ‘fixed’ while the pathogens continue to evolve resistance – therefore all have either become obsolete or are becoming obsolete due to antimicrobial resistance. APT’s PhageBank approach leverages an ever-expanding library of phages that collectively provide an evergreen broad-spectrum and polymicrobial coverage. PhageBank therapy is matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale.

PhageBank is positioned to be the first antimicrobial to increase in the spectrum of coverage and does not require market-suppressing antibiotic stewardship. Advanced development of APT’s therapeutics are funded in part by the US Dept of Defense.

Bacteriophage product pipeline:

PhageBank Therapeutics

  • Prosthetic Joint Infection (PJI)
  • Chronic Recurrent UTI
  • Chronic Wound w/Osteomyelitis

PhageBank Companion Diagnostics

  • HRQT Phage Susceptibility Test

APT Vaccines

  • COVID-19 Vaccine

This website uses cookies. Accept Read More